Protagenic Therapeutics, Inc.
PTIX
$1.57
-$0.08-4.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 148.40% | 169.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 213.42% | 275.51% | |||
| Operating Income | -213.42% | -275.51% | |||
| Income Before Tax | -48.66% | -1,471.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -49.30% | -1,459.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -49.30% | -1,459.03% | |||
| EBIT | -213.42% | -275.51% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -335.77% | -2,173.54% | |||
| Normalized Basic EPS | -333.33% | -2,189.54% | |||
| EPS Diluted | -335.77% | -2,173.54% | |||
| Normalized Diluted EPS | -333.33% | -2,189.54% | |||
| Average Basic Shares Outstanding | -65.72% | -31.40% | |||
| Average Diluted Shares Outstanding | -65.72% | -31.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||